The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
A polymer-coated, paclitaxel-eluting stent (Eluvia) versus a polymer-free, paclitaxel-coated stent (Zilver PTX) for endovascular femoropopliteal intervention (IMPERIAL): a randomised, non-inferiority trial
Abstract
BACKGROUND The clinical effect of a drug-eluting stent in the femoropopliteal segment has not been investigated in a randomised trial with a contemporary comparator. The IMPERIAL study sought to compare the safety and efficacy of the polymer-coated, paclitaxel-eluting Eluvia stent with the polymer-free, paclitaxel-coated Zilver PTX stent for treatment of femoropopliteal artery segment lesions. METHODS In this randomised, single-blind, non-inferiority study, patients with symptomatic lower-limb ischaemia manifesting as claudication (Rutherford category 2, 3, or 4) with atherosclerotic lesions in the native superficial femoral artery or proximal popliteal artery were enrolled at 65 centres in Austria, Belgium, Canada, Germany, Japan, New Zealand, and the USA. Patients were randomly assigned (2:1) with a site-specific, web-based randomisation schedule to receive treatment with Eluvia or Zilver PTX. All patients, site personnel, and investigators were masked to treatment assignment until all patients had completed 12 months of follow-up. The primary efficacy endpoint was primary patency (defined as a peak systolic velocity ratio ≤2·4, without clinically driven target lesion revascularisation or bypass of the target lesion) and the primary safety endpoint was major adverse events (ie, all causes of death through 1 month, major amputation of target limb through 12 months, and target lesion revascularisation through 12 months). We set a non-inferiority margin of -10% at 12 months. Primary non-inferiority analyses were done when the minimum sample size required for adequate statistical power had completed 12 months of follow-up. The primary safety non-inferiority analysis included all patients who had completed 12 months of follow-up or had a major adverse event through 12 months. This trial is registered with ClinicalTrials.gov, number NCT02574481. FINDINGS Between Dec 2, 2015, and Feb 15, 2017, 465 patients were randomly assigned to Eluvia (n=309) or to Zilver PTX (n=156). Non-inferiority was shown for both efficacy and safety endpoints at 12 months: primary patency was 86·8% (231/266) in the Eluvia group and 81·5% (106/130) in the Zilver PTX group (difference 5·3% [one-sided lower bound of 95% CI -0·66]; p<0·0001). 259 (94·9%) of 273 patients in the Eluvia group and 121 (91·0%) of 133 patients in the Zilver PTX group had not had a major adverse event at 12 months (difference 3·9% [one-sided lower bound of 95% CI -0·46]; p<0.0001). No deaths were reported in either group. One patient in the Eluvia group had a major amputation and 13 patients in each group required target lesion revascularisation. INTERPRETATION The Eluvia stent was non-inferior to the Zilver PTX stent in terms of primary patency and major adverse events at 12 months after treatment of patients for femoropopliteal peripheral artery disease. FUNDING Boston Scientific.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II)
Norgren, L., Hiatt, W. R., Dormandy, J. A., Nehler, M. R., Harris, K. A., & Fowkes, F. G. R. (2007) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2006.12.037 · Cited by 8,191
Recommended standards for reports dealing with lower extremity ischemia: Revised version
Rutherford, R. B., Baker, J. D., Ernst, C., Johnston, K. W., Porter, J. M., Ahn, S., & Jones, D. N. (1997) · Journal of Vascular Surgery · doi:10.1016/s0741-5214(97)70045-4 · Cited by 3,562
Aboyans, V., Ricco, J.-B., Bartelink, M.-L. E. L., Björck, M., Brodmann, M., Cohnert, T., Collet, J.-P., Czerny, M., De Carlo, M., Debus, S., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx095 · Cited by 3,293
Self-citationEpidemiology of Peripheral Artery Disease
Criqui, M. H., & Aboyans, V. (2015) · Circulation Research · doi:10.1161/circresaha.116.303849 · Cited by 1,785
Trial of a Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease
Rosenfield, K., Jaff, M. R., White, C. J., Rocha-Singh, K., Mena-Hurtado, C., Metzger, D. C., Brodmann, M., Pilger, E., Zeller, T., Krishnan, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1406235 · Cited by 686
Self-citationTepe, G., Laird, J., Schneider, P., Brodmann, M., Krishnan, P., Micari, A., Metzger, C., Scheinert, D., Zeller, T., Cohen, D. J., et al. (2015) · Circulation · doi:10.1161/circulationaha.114.011004 · Cited by 685
Self-citationAnderson, J. L., Halperin, J. L., Albert, N., Bozkurt, B., Brindis, R. G., Curtis, L. H., DeMets, D., Guyton, R. A., Hochman, J. S., Kovacs, R. J., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.01.004 · Cited by 664
Dake, M. D., Ansel, G. M., Jaff, M. R., Ohki, T., Saxon, R. R., Smouse, H. B., Zeller, T., Roubin, G. S., Burket, M. W., Khatib, Y., et al. (2011) · Circulation: Cardiovascular Interventions · doi:10.1161/circinterventions.111.962324 · Cited by 569
Self-citationDake, M. D., Ansel, G. M., Jaff, M. R., Ohki, T., Saxon, R. R., Smouse, H. B., Machan, L. S., Snyder, S. A., O’Leary, E. E., Ragheb, A. O., et al. (2016) · Circulation · doi:10.1161/circulationaha.115.016900 · Cited by 528
Self-citationDuda, S. H., Bosiers, M., Lammer, J., Scheinert, D., Zeller, T., Oliva, V., Tielbeek, A., Anderson, J., Wiesinger, B., Tepe, G., et al. (2006) · Journal of Endovascular Therapy · doi:10.1583/05-1704.1 · Cited by 490
Self-citation
Cited by
Gornik, H. L., Aronow, H. D., Goodney, P. P., Arya, S., Brewster, L. P., Byrd, L., Chandra, V., Drachman, D. E., Eaves, J. M., Ehrman, J. K., et al. (2024) · Circulation · doi:10.1161/cir.0000000000001251 · Cited by 771
Gornik, H. L., Aronow, H. D., Goodney, P. P., Arya, S., Brewster, L. P., Byrd, L., Chandra, V., Drachman, D. E., Eaves, J. M., Ehrman, J. K., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.02.013 · Cited by 294
Metadata
- Authors
- Gray, W. A., Keirse, K., Soga, Y., Benko, A., Babaev, A., Yokoi, Y., Schroeder, H., Prem, J. T., Holden, A., Popma, J., Jaff, M. R., Diaz-Cartelle, J., Müller-Hülsbeck, S., Albrecht, T., Ando, K., Babaev, A., Bacharach, M. J., Bachinsky, W., Bajakian, D., Beasley, R., Benenati, J., Benko, A., Burket, M., Cardenas, J., Das, T., De Martino, R., Deutschmann, H., Dulas, D., Feldman, R., Fugate, M., Garcia, L., Golzar, J., Gutta, R., Hall, P., Hawkins, S., Henao, S., Herdrich, B., Hirano, K., Holden, A., Jaalouk, S., Janzer, S., Kawasaki, D., Keirse, K., Khatib, Y., Kichikawa, K., Korngold, E., Loewe, C., Lopez, L., Lui, H., Mano, T., Mendes, R., Miyamoto, A., Müller-Hülsbeck, S., Nakamura, M., O'Connor, D., Ohki, T., Park, J., Powell, R., Pratsos, A., Prem, J., Rao, V., Rashid, J., Rhee, R., Ricci, J., Scheinert, D., Schroë, H., Schroeder, H., Simon, P. O., Singh, G., Tan, K., Tolerico, P., Vasudevan, T., Vermassen, F., Werner, M., Wiechmann, B., Yokoi, H., Yokoi, Y., & Zeller, T.
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2018-10
- Volume
- 392
- Issue
- 10157
- Pages
- 1541-1551
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2891944790
- Cited by
- 300
- References
- 18
- FWCI
- 27.10
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A polymer-coated, paclitaxel-eluting stent (Eluvia) versus a polymer-free, paclitaxel-coated stent (Zilver PTX) for endovascular femoropopliteal intervention (IMPERIAL): a randomised, non-inferiority trial. https://app.cochat.ai/papers/10.1016/s0140-6736(18)32262-1
- The paper
- Gray, W. A., Keirse, K., Soga, Y., Benko, A., Babaev, A., Yokoi, Y., Schroeder, H., Prem, J. T., Holden, A., Popma, J., Jaff, M. R., Diaz-Cartelle, J., Müller-Hülsbeck, S., Albrecht, T., Ando, K., Babaev, A., Bacharach, M. J., Bachinsky, W., Bajakian, D., . . . Zeller, T. (2018). A polymer-coated, paclitaxel-eluting stent (Eluvia) versus a polymer-free, paclitaxel-coated stent (Zilver PTX) for endovascular femoropopliteal intervention (IMPERIAL): a randomised, non-inferiority trial. The Lancet. https://doi.org/10.1016/s0140-6736(18)32262-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.